基于生理学的药理动力学建模,以预测不同CYP2D6表型中的可代因的药理动力学
Yujie Yang1, Xiqian Zhang1, Yirong Wang1
1Department of Pharmacy, The Third People's Hospital of Chengdu, College of Medicine, Southwest Jiaotong University, Chengdu, China.
Frontiers in pharmacology
|May 17, 2024
概括
基于生理学的药理动力学模型揭示了CYP2D6遗传变异如何影响代因和吗啡水平. 由于减少了吗啡暴露,可代因在低代谢者的疼痛缓解效果较低.
科学领域:
- 药理学 药理学是指药理学的学科.
- 药物遗传学 药物遗传学
- 计算生物学 计算生物学
背景情况:
- 柯代因是一种阿片类前药物,由酶CYP2D6.6代谢成活性吗啡.
- CYP2D6表现出显著的遗传多态性,导致不同的代谢表型 (例如,低,中等,广泛和超快代谢者).
- 了解这些遗传变异如何影响可代因的药理动力学对于优化疼痛管理和确保患者安全至关重要.
研究的目的:
- 开发和验证可代因及其活性代谢物吗啡的生理学基础的药理动力学 (PBPK) 模型.
- 调查CYP2D6遗传多态性对可代因和吗啡的药理学特征的影响.
- 评估这些变化对可代因剂量和疗效的影响.
主要方法:
- 使用PK-Sim®软件构建了PBPK模型,并根据观察到的药理动力学数据进行了验证.
- 模型被推断为模拟不同的CYP2D6表型:超快速 (UM),广泛 (EM),中间 (IM) 和低代谢 (PM).
- 使用平均折叠误差 (MFE) 和几何平均折叠误差 (GMFE) 度量来评估模型的准确性.
主要成果:
- 经过验证的PBPK模型准确地预测了在各种CYP2D6表型中可代因和吗啡的处置.
- 与EM相比,PM (98.6%) 和IM (60.84%) 中的吗啡暴露 (AUC0-∞) 显着较低,但在UM (73.43%) 中更高.
- 在IM中服用80毫克的可代因剂量与EM中服用30毫克的吗啡剂量产生了类似的吗啡暴露,这表明需要调整剂量.
结论:
- PBPK建模是预测由于CYP2D6遗传多态化的可代因的药物动力学变异性的宝贵工具.
- 由于吗啡水平较低,可代因对缓解疼痛的疗效可能在PM中不足.
- 未来的应用包括预测涉及可代因的药物相互作用,并指导个性化剂量策略.
相关概念视频
Pharmacokinetic Models: Comparison and Selection Criterion
69
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
69
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
38
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
38
Pharmacokinetic Models: Overview
665
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
665
Model Approaches for Pharmacokinetic Data: Physiological Models
42
Physiological models in pharmacokinetics are instrumental in understanding the distribution and elimination of drugs within the body. These models describe the drug concentration within target organs, influenced by factors such as drug uptake, tissue volume, and blood flow. Drug uptake is governed by the partition coefficient, which signifies the drug concentration ratio in tissue to that in the blood. The blood flow rate to a specific tissue is expressed as Qt, and the rate of change in tissue...
42
Analysis of Population Pharmacokinetic Data
252
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
252
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models
68
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
68


